Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials.
Lancet
November 2010
Division of Physiotherapy, School of Health and Rehabilitation Sciences, University of Queensland, St Lucia, Queensland, Australia.
Background: Few evidence-based treatment guidelines for tendinopathy exist. We undertook a systematic review of randomised trials to establish clinical efficacy and risk of adverse events for treatment by injection.
Methods: We searched eight databases without language, publication, or date restrictions.
Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia.
Eur J Haematol
March 2001
Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-University Greifswald, Sauerbruchstr/Diagnostikzentrum, 17487 Greifswald, Germany.
Objective: To assess the crossreactivity of glucosamine sulfate, used for treatment of degenerative joint disease with antibodies induced in heparin-induced thrombocytopenia (HIT).
Background: HIT is a severe adverse effect of heparin therapy induced by an immunological mechanism. The antibodies in HIT are induced by a complex of heparin and, in most cases, platelet factor 4.
[Effects of rumalon and arteparon correcting metabolism in the connective tissue on the functional state of the liver in toxic hepatitis].
Eksp Klin Farmakol
December 2000
Clinical Pharmacy Department, Ukrainian Pharmaceutical Academy, Kharkov, Ukraine.
Effects of the connective tissue metabolism correctors rumalon (a glycosaminoglycane peptide complex) and arteparon (glucosamine sulfate) on the cholepoietic and absorption-excretion functions of liver were studied on a model of toxic liver damage. Rumalon exhibits pronounced anticholelithiasis and cholagogic properties and improves the absorption-excretion liver function. Arteparon produced no cholagogic action, inhibited the elimination of bromosulfalein, and showed no anticholelithiasis activity.
View Article and Find Full Text PDFAim: To improve the efficacy of osteoarthrosis (AO) treatment by chondroprotectors by defining individual indications for their use, based on the initial level of antibodies to cartilaginous glycosaminoglycans (GAG) in the blood serum.
Materials And Methods: Anti-GAG were detected by indirect solid-phase enzyme immunoassay. The antigen was a sulfated GAG preparation GAG-polysulfate (arteparon) manufactured by Luitpold-Werk (Germany).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!